Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study. - 75-day observed half-life supports ...
− If approved, the additional treatment modality will provide more options for how patients in Europe receive the gut-selective biologic vedolizumab − Recommendation brings vedolizumab one step closer ...
The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback